[Analysis of the clinical efficacy and safety of dupilumab in the treatment of patients with moderate to severe atopic dermatitis complicated with asthma].

<b>Objective:</b> To investigate clinical efficacy and safety of dupilumab in the treatment of moderate to severe atopic dermatitis (AD) complicated with asthma. <b>Methods:</b> A self-controlled study before and after treatment was conducted to retrospectively analyze 45 patients with moderate to severe atopic dermatitis combined with asthma who received dupilumab in the respiratory allergy clinic of North Theater Command General Hospital from January 2021 to May 2024, which age ≥12 years, including 27 males, 18 females. The treatment period was 4 to 12 months. All patients were treated with dupilumab combined with inhaled glucocorticoids and long-acting beta2-receptor agonists, as well as symptomatic drugs for atopic dermatitis. Analyze the clinical data of the patients before and after treatment, including lung function, asthma and AD-related assessment scales. Generalized estimation equation was used to analyze the simple effect of time on the repeated measurement data following non-normal distribution, and Wilcoxon signed rank test was used to compare the differences of each observation index before and after treatment. <b>Results:</b> Among 45 patients with moderate to severe atopic dermatitis complicated with asthma, after treatment with dupilumab, the FEV₁ increased from 2.39 (1.87, 2.83) L at baseline to 2.50 (1.84, 2.97) L 3 months after treatment (<i>Z</i>=2.417, <i>P</i>=0.016), 2.60 (1.95, 3.14) L 6 months after treatment (<i>Z</i>=2.896, <i>P</i>=0.004); the FEV₁pred% increased from 74.10% (67.70%, 78.75%) at baseline to 77.09% (68.40%, 80.24%) at 3 months after treatment (<i>Z</i>=2.574, <i>P</i>=0.010), and 77.20% (71.10%, 80.72%) at 6 months after treatment (<i>Z</i>=2.861, <i>P</i>=0.004). Meanwhile, there were statistically significant differences in the ACT and Mini-AQLQ scales at 3, 6, and 12 months after treatment compared with those before treatment (ACT score <i>Z</i>=3.170, 4.216, 5.723; Mini-AQLQ score <i>Z</i>=3.231, 4.133, 5.826; all <i>P</i><0.05). The EASI scale decreased from baseline 25.90 (18.95, 33.45) to 6.20 (1.15, 8.35) at 4 months after treatment (<i>Z</i>=5.842, <i>P</i><0.05) and 4.90 (2.75, 8.35) at 6 months after treatment (<i>Z</i>=5.841, <i>P</i><0.05), 4.00 (3.15, 5.05) at 12 months after treatment (<i>Z</i>=5.841, <i>P</i><0.05); The scores of each scale of IGA, NRS and DLQI decreased significantly compared with the baseline after 4 months, 6 months and 12 months of treatment, and this trend became more obvious with the extension of treatment time. The differences were statistically significant (IGA score <i>Z</i>=6.247, 6.070, 5.946; NRS score <i>Z</i>=5.960, 5.893, 5.879; DLQI score <i>Z</i>=5.880, 5.850, 5.848; all <i>P</i><0.05). During treatment, 1 patient had local adverse reactions at the injection site and 1 patient had conjunctivitis. <b>Conclusion:</b> Dupilumab may have a positive effect on improving the clinical efficacy of patients with moderate to severe atopic dermatitis complicated with asthma. During the 12-month observation period, this biological agent generally demonstrated good safety characteristics.